ESC 365 - Glucose lowering drugs with proven cardiovascular benefit following acute coronary syndrome in type 2 diabetes: treatment gaps and outcomes

ESC Professional Premium Access

Glucose lowering drugs with proven cardiovascular benefit following acute coronary syndrome in type 2 diabetes: treatment gaps and outcomes

Session: Obesity and diabetes: risk assessment and prognosis

Topic: Pharmacotherapy

Speaker: Doctor I. Naoum (Haifa, IL)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Ibrahim Naoum

Lady Davis Carmel Medical Center, Haifa (Israel)

1 presentation

0 follower

4 more presentations in this session

Persistence and Adherence to GLP-1 RA treatment in Type 2 Diabetes Mellitus: a Nationwide registry study

Speaker: Doctor M. Lassen (Boston, US)

Cardiovascular disease risk in people with diabetes in the era of universal diabetes screening

Speaker: Miss J. Liang (Auckland, NZ)

Prognostic outcomes of masld and obesity in acute myocardial infarction

Speaker: Doctor G. Kong (Singapore, SG)

Interleukin-6 and suPAR improves prediction of all-cause mortality in type 1 diabetes - the Thousand & 1 Study

Speaker: Doctor H. Bahrami (Herlev, DK)

Access the full session

Obesity and diabetes: risk assessment and prognosis

Speakers: Doctor I. Naoum, Doctor M. Lassen, Miss J. Liang, Doctor G. Kong, Doctor H. Bahrami

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources